The cckOMA syndrome and its relation to the Zollinger–Ellison syndrome: a diagnostic challenge

References

• Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72. doi: 10.1016/S1470-2045(07)70410-2.
   PubMed Web of Science ®Google Scholar
• Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40(1):1–18, vii. doi: 10.1016/j.ecl.2010.12.005.
   PubMed Web of Science ®Google Scholar
• de Herder WW, Rehfeld JF, Kidd M, et al. A short history of neuroendocrine tumours and their peptide hormones. Best Pract Res Clin Endocrinol Metab. 2016;30(1):3–17. doi: 10.1016/j.beem.2015.10.004.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Cholecystokinin and the hormone concept. Endocr Connect. 2021;10(3):R139–R150. doi: 10.1530/EC-21-0025.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Immunochemical studies on cholecystokinin. II. Distribution and molecular heterogeneity in the Central nervous system and small intestine of man and hog. J Biol Chem. 1978;253(11):4022–4030. doi: 10.1016/S0021-9258(17)34793-2.
   PubMed Web of Science ®Google Scholar
• Larsson LI, Rehfeld JF. Localization and molecular heterogeneity of cholecystokinin in the Central and peripheral nervous system. Brain Res. 1979;165(2):201–218. doi: 10.1016/0006-8993(79)90554-7.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Hansen HF. Characterization of preprocholecystokinin products in the porcine cerebral cortex. Evidence of different processing pathways. J Biol Chem. 1986;261(13):5832–5840.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Lindholm J, Andersen BN, et al. Pituitary tumors containing cholecystokinin. N Engl J Med. 1987;316(20):1244–1247. doi: 10.1056/NEJM198705143162004.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Johnsen AH, Odum L, et al. Non-sulfated cholecystokinin in human medullary thyroid carcinomas. J Endocrinol. 1990;124(3):501–506. doi: 10.1677/joe.0.1240501.
   PubMed Web of Science ®Google Scholar
• Bardram L, Hilsted L, Rehfeld JF. Cholecystokinin, gastrin and their precursors in pheochromocytomas. Acta Endocrinol (Copenh). 1989;120(4):479–484. doi: 10.1530/acta.0.1200479.
   PubMedGoogle Scholar
• Reubi JC, Koefoed P, Hansen T, et al. Procholecystokinin as marker of human Ewing sarcomas. Clin Cancer Res. 2004;10(16):5523–5530. doi: 10.1158/1078-0432.CCR-1015-03.
   PubMed Web of Science ®Google Scholar
• Oikonomou E, Buchfelder M, Adams EF. Cholecystokinin (CCK) and CCK receptor expression by human gliomas: evidence for an autocrine/paracrine stimulatory loop. Neuropeptides. 2008;42(3):255–265. doi: 10.1016/j.npep.2008.02.005.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, van Solinge WW, Tos M, et al. Gastrin, cholecystokinin and their precursors in acoustic neuromas. Brain Res. 1990;530(2):235–238. doi: 10.1016/0006-8993(90)91288-r.
   PubMed Web of Science ®Google Scholar
• Madsen OD, Larsson LI, Rehfeld JF, et al. Cloned cell lines from a transplantable islet cell tumor are heterogeneous and express cholecystokinin in addition to islet hormones. J Cell Biol. 1986;103(5):2025–2034. doi: 10.1083/jcb.103.5.2025.
   PubMed Web of Science ®Google Scholar
• Madsen OD, Karlsen C, Nielsen E, et al. The dissociation of tumor-induced weight loss from hypoglycemia in a transplantable pluripotent rat islet tumor results in the segregation of stable alpha- and beta-cell tumor phenotypes. Endocrinology. 1993;133(5):2022–2030. doi: 10.1210/endo.133.5.8404649.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Federspiel B, Bardram L. A neuroendocrine tumor syndrome from cholecystokinin secretion. N Engl J Med. 2013;368(12):1165–1166. doi: 10.1056/NEJMc1215137.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Federspiel B, Agersnap M, et al. The uncovering and characterization of a CCKoma syndrome in enteropancreatic neuroendocrine tumor patients. Scand J Gastroenterol. 2016;51(10):1172–1178. doi: 10.1080/00365521.2016.1183706.
   PubMed Web of Science ®Google Scholar
• Jensen RT. Gastrinoma as a model for prolonged hypergastrinemia in man. In Walsh JH, editor. Gastrin. New York: Raven Press Publishing Co. 1993:pp. 373–393.
   Google Scholar
• Jensen RT. Recent insights from studies of gastrinomas. In: merchant JL, Buchan AMJ, Wang TC, editors. Gastrin in the new millenium. CURE Foundation: Los Angeles, CA, USA, 2004:pp. 339–352.
   Google Scholar
• Agersnap M, Rehfeld JF. Nonsulfated cholecystokinins in the small intestine of pigs and rats. Peptides. 2015;71:121–127. doi: 10.1016/j.peptides.2015.07.010.
   PubMed Web of Science ®Google Scholar
• Gilliam-Vigh H, Jorsal T, Rehfeld JF, et al. Expression of cholecystokinin and its receptors in the intestinal tract of type 2 diabetes patients and healthy controls. J Clin Endocrinol Metab. 2021;106(8):2164–2170. doi: 10.1210/clinem/dgab367.
   PubMed Web of Science ®Google Scholar
• Martins P, Fakhry J, de Oliveira EC, et al. Analysis of enteroendocrine cell populations in the human Colon. Cell Tissue Res. 2017;367(2):161–168. doi: 10.1007/s00441-016-2530-7.
   PubMed Web of Science ®Google Scholar
• Fakhry J, Wang J, Martins P, et al. Distribution and characterisation of CCK containing enteroendocrine cells of the mouse small and large intestine. Cell Tissue Res. 2017;369(2):245–253. doi: 10.1007/s00441-017-2612-1.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. The endoproteolytic maturation of progastrin and procholecystokinin. J Mol Med (Berl). 2006;84(7):544–550. doi: 10.1007/s00109-006-0055-3.
   PubMed Web of Science ®Google Scholar
• Dufresne M, Seva C, Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev. 2006;86(3):805–847. doi: 10.1152/physrev.00014.2005.
   PubMed Web of Science ®Google Scholar
• Ding XQ, Lindström E, Håkanson R. Evaluation of three novel cholecystokinin-B/gastrin receptor antagonists: a study of their effects on rat stomach enterochromaffin-like cell activity. Pharmacol Toxicol. 1997;81(5):232–237. doi: 10.1111/j.1600-0773.1997.tb00052.x.
   PubMedGoogle Scholar
• Reubi JC, Waser B, Gugger M, et al. Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. Gastroenterology. 2003;125(1):98–106. doi: 10.1016/s0016-5085(03)00697-8.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Sun G, Christensen T, et al. The predominant cholecystokinin in human plasma and intestine is cholecystokinin-33. J Clin Endocrinol Metab. 2001;86(1):251–258. doi: 10.1210/jc.86.1.251.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Accurate measurement of cholecystokinin in plasma. Clin Chem. 1998;44(5):991–1001. doi: 10.1093/clinchem/44.5.991.
   PubMed Web of Science ®Google Scholar
• Veedfald S, Rehfeld JF, van Hall G, et al. Entero-pancreatic hormone secretion, gastric emptying, and glucose absorption after frequently sampled meal tests. J Clin Endocrinol Metab. 2022;107(1):e188–e204. doi: 10.1210/clinem/dgab610.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Cholecystokinin. In Maklouf GM, handbook of physiology, section 6., vol. II. Amer Physiol Soc., Bethesda (Md), 1989:pp. 337–358.
   Google Scholar
• Liddle RA. Cholecystokinin. In: Walsh JH, Dockray GJ, editors. Gut peptides: biochemistry and physiology. Raven Press Ltd., New York, 1994:pp. 175–216.
   Google Scholar
• Rehfeld JF. Cholecystokinin – from local gut hormone to ubiquitous messenger. Front Endocrinol (Lausanne). 2017;8art. :47. doi: 10.3389/fendo.2017.00047.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiol (Oxf). 2011;201(4):405–411. doi: 10.1111/j.1748-1716.2010.02235.x.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. The origin and understanding of the incretin concept. Front Endocrinol (Lausanne). 2018;9art. :387. doi: 10.3389/fendo.2018.00387.
   PubMed Web of Science ®Google Scholar
• Henriksen FW, Worning H. The interaction of secretin and pancreozymin on the exocrine pancreatic secretion in dogs. Acta Physiol Scand. 1969;76(1):67–72. doi: 10.1111/j.1748-1716.1969.tb04451.x.
   PubMedGoogle Scholar
• Wormsley KGA. A comparison of the response to secretin, pancreozymin and a combination of these hormones in man. Scand J Gastroenterol. 1969;4(5):413–417. doi: 10.3109/00365526909180626.
   Web of Science ®Google Scholar
• Vana V, Laerke MK, Rehfeld JF, et al. Vagal afferent cholecystokinin receptor activation is required for glucagon-like peptide-1-induced satiation. Diabetes Obes Metab. 2022;24(2):268–280. doi: 10.1111/dom.14575.
   PubMed Web of Science ®Google Scholar
• Chen D, Zhao CM, Håkanson R, et al. Altered control of gastric acid secretion in gastrin-cholecystokinin double mutant mice. Gastroenterology. 2004;126(2):476–487. doi: 10.1053/j.gastro.2003.11.012.
   PubMed Web of Science ®Google Scholar
• Asmar M, Bache M, Knop FK, et al. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans? J Clin Endocrinol Metab. 2010;95(5):2367–2375. doi: 10.1210/jc.2009-2133.
   PubMed Web of Science ®Google Scholar
• Brown JC. A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. Can J Biochem. 1971;49(2):255–261. doi: 10.1139/o71-037.
   PubMedGoogle Scholar
• Shively J, Reeve JR, Jr, Eysselein VE, et al. CCK-5: sequence analysis of a small cholecystokinin from canine brain and intestine. Am J Physiol. 1987;252(2 Pt 1):G272–G275. doi: 10.1152/ajpgi.1987.252.2.G272.
   PubMedGoogle Scholar
• Cantor P, Rehfeld JF. Cholecystokinin in pig plasma: release of components devoid of a bioactive COOH-terminus. Am J Physiol. 1989;256(1 Pt 1):G53–G61. doi: 10.1152/ajpgi.1989.256.1.G53.
   PubMedGoogle Scholar
• Rehfeld JF, Agersnap M. Unsulfated cholecystokinin: an overlooked hormone? Regul Pept. 2012;173(1-3):1–5. doi: 10.1016/j.regpep.2011.09.009.
   PubMedGoogle Scholar
• Agersnap M, Rehfeld JF. Measurement of nonsulfated cholecystokinins. Scand J Clin Lab Invest. 2014;74(5):424–431. doi: 10.3109/00365513.2014.900695.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Bundgaard JR, Hannibal J, et al. The cell-specific pattern of cholecystokinin peptides in endocrine cells versus neurons is governed by the expression of prohormone convertases 1/3, 2, and 5/6. Endocrinology. 2008;149(4):1600–1608. doi: 10.1210/en.2007-0278.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, van Solinge WW. The tumor biology of gastrin and cholecystokinin. Adv Cancer Res. 1994;63:295–347. doi: 10.1016/s0065-230x(08)60403-0.
   PubMed Web of Science ®Google Scholar
• Paloheimo LI, Rehfeld JF. Quantitation of procholecystokinin and its products in plasma by processing-independent analysis. Clin Chim Acta. 1995;238(1):21–33. doi: 10.1016/0009-8981(95)06055-i.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Cholecystokinin expression in tumors: biogenetic and diagnostic implications. Future Oncol. 2016;12(18):2135–2147. doi: 10.2217/fon-2015-0053.
   PubMed Web of Science ®Google Scholar
• Zollinger RM, Ellison EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg. 1955;142(4):709–728.
   PubMed Web of Science ®Google Scholar
• Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med. 1987;317(19):1200–1209. doi: 10.1056/NEJM198711053171907.
   PubMed Web of Science ®Google Scholar
• Stadil F, Rehfeld JF. Determination of gastrin in serum. Eval Reliability Radioimmunoassay. Scand J Gastroenterol. 1973;8(2):101–112. doi: 10.1080/00365521.1973.12096677.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Gingras MH, Bardram L, et al. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology. 2011;140(5):1444–1453. doi: 10.1053/j.gastro.2011.01.051.
   PubMed Web of Science ®Google Scholar
• Kopin AS, Lee YM, McBride EW, et al. Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A. 1992;89(8):3605–3609. doi: 10.1073/pnas.89.8.3605.
   PubMed Web of Science ®Google Scholar
• Larsson LI, Goltermann N, de Magistris L, et al. Somatostatin cell processes as pathways for paracrine secretion. Science. 1979;205(4413):1393–1395. doi: 10.1126/science.382360.
   PubMed Web of Science ®Google Scholar
• Makhlouf GM, Schubert ML. Gastric somatostatin: a paracrine regulator of acid secretion. Metabolism. 1990;39(9 Suppl 2):138–142. doi: 10.1016/0026-0495(90)90232-2.
   PubMed Web of Science ®Google Scholar
• Lloyd KC, Raybould HE, Walsh JH. Cholecystokinin inhibits gastric acid secretion through type "a" cholecystokinin receptors and somatostatin in rats. Am J Physiol. 1992;263(3 Pt 1):G287–G292. doi: 10.1152/ajpgi.1992.263.3.G287.
   PubMedGoogle Scholar
• Chen D, Zhao CM, Al-Haider W, et al. Differentiation of gastric ECL cells is altered in CCK(2) receptor-deficient mice. Gastroenterology. 2002;123(2):577–585. doi: 10.1053/gast.2002.34746.
   PubMed Web of Science ®Google Scholar
• Andersen BN, Stadil F. Sulfation of gastrin in zollinger–ellison sera: evidence for association between sulfation and proteolytic processing. Regul Pept. 1983;6(3):231–239. doi: 10.1016/0167-0115(83)90141-6.
   PubMedGoogle Scholar
• Andersen BN, Petersen B, Borch K, et al. Variations in the sulfation of circulating gastrins in gastrointestinal diseases. Scand J Gastroenterol. 1983;18(4):565–569. doi: 10.3109/00365528309181639.
   PubMed Web of Science ®Google Scholar
• Jensen S, Borch K, Hilsted L, et al. Progastrin processing during antral G-cell hypersecretion in humans. Gastroenterology. 1989;96(4):1063–1070. doi: 10.1016/0016-5085(89)91624-7.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Stadil F, Rubin B. Production and evaluation of antibodies for the radioimmunoassay of gastrin. Scand J Clin Lab Invest. 1972;30(2):221–232. doi: 10.3109/00365517209081114.
   PubMed Web of Science ®Google Scholar
• Bardram L, Rehfeld JF. Processing-independent radioimmunoanalysis: a general analytical principle applied to progastrin and its products. Anal Biochem. 1988;175(2):537–543. doi: 10.1016/0003-2697(88)90580-5.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Goetze JP. The posttranslational phase of gene expression: new possibilities in molecular diagnosis. Curr Mol Med. 2003;3(1):25–38. doi: 10.2174/1566524033361717.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Goetze JP. Processing-independent analysis (PIA): a method for quantitation of the total peptide-gene expression. Peptides. 2021;135:170427. doi: 10.1016/j.peptides.2020.170427.
   PubMed Web of Science ®Google Scholar
• Corleto VD, Annibale B, Gibril F, et al. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther. 2001;15(10):1555–1561. doi: 10.1046/j.1365-2036.2001.01085.x.
   PubMed Web of Science ®Google Scholar
• Ito T, Cadiot G, Jensen RT. Diagnosis of zollinger ellison syndrome: increasingly difficult. World J Gastroenterol. 2012;18(39):5495–5503. doi: 10.3748/wjg.v18.i39.5495.
   PubMed Web of Science ®Google Scholar
• Metz DC. Diagnosis of the Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol. 2012;10(2):126–130. doi: 10.1016/j.cgh.2011.07.012.
   PubMed Web of Science ®Google Scholar
• Raines D, Chester M, Diebold AE, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas. 2012;41(4):508–511. doi: 10.1097/MPA.0b013e318243a0b6.
   PubMed Web of Science ®Google Scholar
• Metz DC, Cadiot G, Poitras P, et al. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol. 2017;4(4):167–185. doi: 10.2217/ije-2017-0018.
   PubMed Web of Science ®Google Scholar
• Rossi RE, Elvevi A, Citterio D, et al. Gastrinoma and Zollinger-Ellison syndrome: a roadmap for the management between new and old therapies. World J Gastroenterol. 2021;27(35):5890–5907. doi: 10.3748/wjg.v27.i35.5890.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. Gastrin and the moderate hypergastrinemias. Int J Mol Sci. 2021;22(13):6977. doi: 10.3390/ijms22136977.
   PubMed Web of Science ®Google Scholar
• Børglum T, Rehfeld JF, Drivsholm LB, et al. Processing-independent quantitation of chromogranin A in plasma from patients with neuroendocriine tumors and small-cell lung carcinomas. Clin Chem. 2007;53(3):438–446. doi: 10.1373/clinchem.2006.076158.
   PubMed Web of Science ®Google Scholar
• Massironi S, Rossi RE, Casazza G, et al. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution. Neuroendocrinology. 2014;100(2-3):240–249. doi: 10.1159/000369818.
   PubMed Web of Science ®Google Scholar
• Rossi RE, Ciafardini C, Sciola V, et al. Chromogranin A in the follow-up of gastroenteropancratic neuroendocrine neoplasms. Is it really game over? A systematic review and meta-analysis. Pancreas. 2018;47(10):1249–1255. doi: 10.1097/MPA.0000000000001184.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Broedbaek K, Goetze JP, et al. True Chromogranin A concentrations from patients with small intestinal neuroendocrine tumours. Scand J Gastroenterol. 2020;55(5):565–573. doi: 10.1080/00365521.2020.1759141.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. The art of measuring gastrin in plasma: a dwindling diagnostic discipline? Scand J Clin Lab Invest. 2008;68(5):353–361. doi: 10.1080/00365510701771831.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Stadil F, Vikelsoe J. Immunoreactive gastrin components in human serum. Gut. 1974;15(2):102–111. doi: 10.1136/gut.15.2.102.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF, Johnsen AH. Identification of gastrin component I as gastrin-71. The largest possible bioactive progastrin product. Eur J Biochem. 1994;223(3):765–773. doi: 10.1111/j.1432-1033.1994.tb19051.x.
   PubMedGoogle Scholar
• Rehfeld JF, Hansen CP, Johnsen AH. Post-poly(glu) cleavage and degradation modified by O-sulfated tyrosine: a novel post-translational processing mechanism. Embo J. 1995;14(2):389–396. doi: 10.1002/j.1460-2075.1995.tb07013.x.
   PubMed Web of Science ®Google Scholar
• Schubert ML, Rehfeld JF. Gastric peptides-gastrin and somatostatin. Compr Physiol. 2020;10(1):197–228. doi: 10.1002/cphy.c180035.
   Web of Science ®Google Scholar
• Rehfeld JF. Measurement of cholecystokinin in plasma with reference to nutrition related obesity studies. Nutr Res. 2020;76:1–8. doi: 10.1016/j.nutres.2020.01.003.
   PubMed Web of Science ®Google Scholar
• Rehfeld JF. How to measure cholecystokinin in tissue, plasma and cerebrospinal fluid. Regul Pept. 1998;78(1-3):31–39. doi: 10.1016/s0167-0115(98)00133-5.
   PubMedGoogle Scholar
• Hofland J, Falconi M, Christ E, et al. European neuroendocrine tumor society 2023 guidance for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol. 2023;35(8):e13318. doi: 10.1111/jne.13318.
   PubMedGoogle Scholar